What is AnaBios?
AnaBios operates at the intersection of biotechnology and translational medicine, specializing in the validation of novel compounds through advanced human-centric testing models. By focusing on complex therapeutic areas such as cardiac disease, pain, and itch, the company provides essential data that mitigates risk in the drug development pipeline. Its business model is multifaceted, combining a service-oriented approach for CROs and biotech partners with an internal drug discovery engine fueled by strategic in-licensing agreements. This dual-track strategy allows AnaBios to maintain a sustainable revenue stream while simultaneously building a high-value proprietary pipeline of therapeutic candidates.
How much funding has AnaBios raised?
AnaBios has raised a total of $12.3M across 3 funding rounds:
Series A
$2M
Series B
$10M
Debt
$350K
Series A (2011): $2M with participation from Tech Coast Angels
Series B (2016): $10M led by Principia SGR
Debt (2020): $350K supported by PPP
Key Investors in AnaBios
Principia SGR
Principia SGR is a prominent Italian venture capital firm specializing in the healthcare sector, providing growth capital to startups and SMEs to foster innovation in medical research.
Tech Coast Angels
One of the largest and most active angel investor groups in the United States, focusing on early-stage technology and life science ventures.
PPP
Public-Private Partnership
What's next for AnaBios?
With the recent capital deployment, AnaBios is positioned to scale its internal drug discovery operations and expand its translational technology footprint. The strategic focus will likely shift toward accelerating the development of in-licensed programs and enhancing the throughput of its human-focused screening platforms. As the company matures, the emphasis will remain on securing long-term partnerships with global pharmaceutical leaders, ensuring that its translational insights continue to drive efficiency in the global drug development ecosystem. The current funding context suggests a period of aggressive operational scaling and potential expansion into new therapeutic indications where human-focused data is paramount for regulatory success.
See full AnaBios company page
